# Tumours of the Lung - Small Diagnostic and Cytopathological Specimens Histopathology Reporting Guide

Family/Last name

Given name(s)

Date of birth DD – MM – YYYY

Patient identifiers

Date of request DD – MM – YYYY

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

☐ indicates multi-select values ◯ indicates single select values

SCOPE OF THIS DATASET

## CLINICAL INFORMATION

◯ Information not provided

**Imaging evidence of lung mass**

◯ Information not provided
◯ Not identified
◯ Present, *describe*

**Clinical or imaging evidence of advanced disease**

◯ Information not provided
◯ Not identified
◯ Present, *describe*

**Other clinical information, *specify***

## SPECIMEN TYPE (select all that apply)

**Small biopsy specimens**

◯ Not submitted
☐ Bronchoscopic forceps biopsy
  Number of biopsies
☐ Core needle biopsy
  Gauge of needle
  Number of cores
☐ Cryobiopsy
  Number of biopsies
☐ Surgical biopsy (e.g., supraclavicular nodal metastasis, pathological bone fracture, brain metastasis)
☐ Other, *specify*

**Cytopathology specimens**

◯ Not submitted
☐ Sputum
☐ Bronchial brushings
☐ Bronchial washings
☐ Bronchoalveolar lavage (BAL)
☐ Fine needle aspiration biopsy (FNAB) (Percutaneous)
☐ FNAB (Endoscopic)
  ◯ Transbronchial ◯ Approach not specified
  ◯ Transesophageal
☐ Pleural fluid
☐ Pericardial fluid
☐ Imprints of biopsy specimens
☐ Other, *specify*

## SITE(S) OF SAMPLING (select all that apply)

**Lung**

☐ Left
  ☐ Upper lobe
  ☐ Lower lobe
  ☐ Other (e.g., hilar mass), *specify*

☐ Right
  ☐ Upper lobe
  ☐ Middle lobe
  ☐ Lower lobe
  ☐ Other, *specify*

**Extrapulmonary sites**

Other site 1, *specify*

Other site 2, *specify*

**Nodal sites**[a]

☐ 10 Hilar
  ☐ Left ☐ Right
☐ 11 Interlobar
  ☐ Left ☐ Right
☐ 12 Lobar
  ☐ Left ☐ Right
☐ 2L Upper Paratracheal (left)
☐ 2R Upper Paratracheal (right)
☐ 4L Lower Paratracheal (left)
☐ 4R Lower Paratracheal (right)
☐ 7 Subcarinal
☐ Other, *specify*

[a] *Nodes accessible via EBUS.*


Version 1.1 Published December 2023 ISBN: 978-1-922324-42-9

***This reporting guide is designed to be inclusive of every type of cytopathology specimen. If you are doing cytopathology but not rapid onsite evaluation (ROSE) skip to page 3. If you are only reporting on biopsy specimens skip to page 4.***

**ROSE**

*(Applicable to cytopathology specimens only)*

- ○ Not performed
- ○ Performed
  - ○ In person
  - ○ Via telecytopathology

**Type** (select all that apply)

- ☐ Fine needle aspiration biopsy (FNAB)
- ☐ Other, *specify*

| | Name of site assessed | Number of passes | Number of slides | Type of stain used | Adequate/ Inadequate | Provisional diagnosis by cytopathologist (verbatim) | Biopsy taken at this site |
|---|---|---|---|---|---|---|---|
| Site 1 | | | | | | | |
| Site 2 | | | | | | | |
| Site 3 | | | | | | | |
| Site 4 | | | | | | | |
| Site 5 | | | | | | | |
| Site 6 | | | | | | | |
| Site 7 | | | | | | | |
| Site 8 | | | | | | | |
| Site 9 | | | | | | | |
| Site 10 | | | | | | | |

**Contact details of proceduralist**


Version 1.1 Published December 2023 ISBN: 978-1-922324-42-9

*Complete for second specimen if applicable.*
*If more specimens have been submitted print additional pages.*

**Site, *specify***

**DESCRIPTION AND DISTRIBUTION OF SAMPLED MATERIAL**

**Fluid** (if applicable)

COLLECTION MEDIA

- ◯ None (specimen only)
- ◯ RPMI
- ◯ Saline
- ◯ Formalin
- ◯ Liquid based cytopathology, *specify type*
- ◯ Other, *specify*

Volume mL

Description of fluid (e.g., colour, presence of blood, viscosity, presence of particulate matter), *specify*

**Slides made by direct smear, cytospin or liquid-based cytology from fluid received in laboratory**

Number of air-dried slides

Number of alcohol-fixed slides

**Direct smears submitted to laboratory**

Number of air-dried slides

Number of alcohol-fixed slides

**Distribution** (select all that apply)

- ☐ Flow cytometry
- ☐ Molecular
- ☐ Microbiology
- ☐ Cell block, *specify identifier*
- ☐ Core biopsy, *specify identifier and block number*
- ☐ Other (e.g., tissue bank), *specify*

**CATEGORY**

*(Applicable to cytopathology specimens only)*
*(Values based on the World Health Organization (WHO) Reporting System for Lung Cytopathology (2022))*

- ◯ Inadequate/Insufficient/Non-diagnostic
- ◯ Benign
- ◯ Atypical, *explain reasons*
- ◯ Suspicious for malignancy, *explain reasons*
- ◯ Malignant

**Site, *specify***

**DESCRIPTION AND DISTRIBUTION OF SAMPLED MATERIAL**

**Fluid** (if applicable)

COLLECTION MEDIA

- ◯ None (specimen only)
- ◯ RPMI
- ◯ Saline
- ◯ Formalin
- ◯ Liquid based cytopathology, *specify type*
- ◯ Other, *specify*

Volume mL

Description of fluid (e.g., colour, presence of blood, viscosity, presence of particulate matter), *specify*

**Slides made by direct smear, cytospin or liquid-based cytology from fluid received in laboratory**

Number of air-dried slides

Number of alcohol-fixed slides

**Direct smears submitted to laboratory**

Number of air-dried slides

Number of alcohol-fixed slides

**Distribution** (select all that apply)

- ☐ Flow cytometry
- ☐ Molecular
- ☐ Microbiology
- ☐ Cell block, *specify identifier*
- ☐ Core biopsy, *specify identifier and block number*
- ☐ Other (e.g., tissue bank), *specify*

**CATEGORY**

*(Applicable to cytopathology specimens only)*
*(Values based on the World Health Organization (WHO) Reporting System for Lung Cytopathology (2022))*

- ◯ Inadequate/Insufficient/Non-diagnostic
- ◯ Benign
- ◯ Atypical, *explain reasons*
- ◯ Suspicious for malignancy, *explain reasons*
- ◯ Malignant


Version 1.1 Published December 2023 ISBN: 978-1-922324-42-9

## TUMOUR TYPE

*(Applicable to all histopathology specimens and those cytopathology specimens categorised as malignant)*
*(Values based on the WHO Reporting System for Lung Cytopathology (2022))*

- ◯ Squamous cell carcinoma
- ◯ Non-mucinous adenocarcinoma, *list patterns if possible*
- ◯ Non-mucinous adenocarcinoma with pure lepidic pattern (an invasive component cannot be excluded)
- ◯ Invasive mucinous adenocarcinoma, *list patterns if possible*
- ◯ Mucinous adenocarcinoma with pure lepidic pattern (an invasive component cannot be excluded)
- ◯ Adenocarcinoma with colloid features
- ◯ Adenocarcinoma with fetal features
- ◯ Adenocarcinoma with enteric features
- ◯ Non-small cell carcinoma, favour squamous cell carcinoma
- ◯ Non-small cell carcinoma, favour adenocarcinoma
- ◯ Non-small cell carcinoma NOS
- ◯ Morphological squamous cell and adenocarcinoma patterns both present: non-small cell carcinoma NOS[b,c]
- ◯ Morphological squamous cell or adenocarcinoma patterns not present, but immunohistochemical stains favour separate squamous and adenocarcinoma components: non-small cell carcinoma NOS[b,d]
- ◯ Non-small cell carcinoma with spindle cell and/or giant cell carcinoma
  - ◯ Adenocarcinoma or squamous carcinoma present[e]
  - ◯ Adenocarcinoma and squamous carcinoma absent
- ◯ Carcinoid tumour (neuroendocrine tumour)
- ◯ Small cell carcinoma
- ◯ Non-small cell carcinoma with neuroendocrine morphology and positive neuroendocrine markers, possible large cell neuroendocrine carcinoma
- ◯ Other, *specify*

[b] *Refer to the results of immunohistochemistry (IHC).*

[c] *As adenocarcinoma and squamous components are both present, this could represent adenosquamous carcinoma, but that diagnosis requires a resection specimen.*

[d] *This could represent adenosquamous carcinoma, but that diagnosis requires a resection specimen.*

[e] *This could represent a pleomorphic carcinoma, but that diagnosis requires a resection specimen.*

## REPRESENTATIVE MATERIAL FOR ANCILLARY STUDIES

Core needle biopsy block number and in cytopathology cases the direct smear number, cell block identifier or other identifier (e.g., liquid based cytology), *specify*

Specimen type used, *specify*

**Cellularity**

- ◯ Very low (<100)
- ◯ Low (100-≤2,000)
- ◯ Intermediate (>2,000-≤5,000)
- ◯ High (>5,000)

OR

*Describe*

**Tumour fraction** %

**Necrosis** %

## ANCILLARY STUDIES

**Diagnostic immunohistochemical/immunocytochemical markers**

*(Applicable to cell block and/or core needle biopsy, or smears/cytospins)*

- ◯ Not performed
- ◯ Pending
- ◯ Performed

Material used for testing

- ◯ Cell block
- ◯ Smear or cytospin
- ◯ Biopsy
- ◯ Other, *specify*

Results

| | |
|---|---|
| Positive antibodies | |
| Negative antibodies | |
| Equivocal antibodies | |


Version 1.1 Published December 2023 ISBN: 978-1-922324-42-9

**ANCILLARY STUDIES continued**

**Molecular data**

- ○ Not performed
- ○ Pending
- ○ Performed
  - Material used for testing
    - ○ Cell block
    - ○ Smear
    - ○ Core needle biopsy
    - ○ Other, *specify*

TEST PERFORMED (select all that apply)

- ☐ EGFR result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ ALK result
  - ○ Indeterminate
  - ○ IHC negative
  - ○ IHC positive
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ ROS1 result
  - ○ Indeterminate
  - ○ IHC negative
  - ○ IHC positive
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ RET result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ NTRK result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ BRAF result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ KRAS result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ MET Exon 14 skipping
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ MET Amplification result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*
- ☐ HER2 Mutation result
  - ○ Indeterminate
  - ○ Variant not identified
  - ○ Variant present, *specify*

**Immuno-oncological data**

PD-L1 result

- ○ Not applicable
- >100 tumour cells present
  - ○ Yes
  - ○ No
- Percentage tumour cells positive ____ %
- ○ Indeterminate
- Antibody clone used ____

**Other ancillary studies, *record test(s), methodology and result(s)***


Version 1.1 Published December 2023 ISBN: 978-1-922324-42-9